Skip to main content

Advertisement

SpringerLink
Log in

Mineralocorticoid receptor activation as an etiological factor in kidney diseases

  • Review Article
  • Published:
Clinical and Experimental Nephrology Aims and scope Submit manuscript

Abstract

The mineralocorticoid receptor (MR) is a member of the steroid-responsive nuclear receptor family. Currently, in addition to its classical role in fluid homeostasis, attention has been focused on the pro-proteinuric and pro-inflammatory effects of MR in renal and cardiovascular diseases. Since proteinuria has been shown to be an important factor in the prognosis of patients with chronic kidney disease (CKD) [according to the newest Japanese Society of Nephrology and Kidney Disease: Improving Global Outcomes (KDIGO) guidelines for the treatment of CKD], it is worth discussing the role of MR in the progression of proteinuric CKD and the possible association with podocyte injury. Rac1, a Rho-GTPase family protein, is known for its role in the regulation of the cytoskeleton. We discovered the role of active Rac1 in amplifying MR activation in one of our studies and then continued to study how the Rac1−MR pathway contributes to the progression of kidney diseases. We then discovered the harmful effects of the activation of the Rac1−MR pathway in response to salt loading in the kidney for proteinuric kidney diseases of various animal models with salt-sensitive hypertension, such as Dahl salt-sensitive rats, RhoGDIα-knockout mice, angiotensin II-overproducing mice, and aldosterone-infused rats. In this review, we have introduced recent findings that suggest the contribution of MR activation to kidney diseases and the role of the Rac1−MR pathway in kidney injury associated with salt-sensitive hypertension and proteinuria. Thus, the Rac1−MR pathway is a potential therapeutic target in patients with proteinuric CKD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO. Clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2012;2013(3):1–150.

    Google Scholar 

  2. [Special issue: Clinical practice guidebook for diagnosis and treatment of chronic kidney disease 2012]. Nihon Jinzo Gakkai Shi. 2012;54(8):1034–191.

  3. Chronic Kidney Disease Prognosis Consortium, Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010; 375(9731):2073–81.

  4. Bertocchio JP, Warnock DG, Jaisser F. Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney disease. Kidney Int. 2011;79(10):1051–60.

    Article  CAS  PubMed  Google Scholar 

  5. Mahmoodi BK, Matsushita K, Woodward M, Blankestijn PJ, Cirillo M, Ohkubo T, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis. Lancet. 2012;380(9854):1649–61.

    Article  PubMed  Google Scholar 

  6. Tonelli M, Muntner P, Lloyd A, Manns BJ, Klarenbach S, Pannu N, et al. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study. Lancet. 2012;380(9844):807–14.

    Article  PubMed  Google Scholar 

  7. Astor BC, Matsushita K, Gansevoort RT, van der Velde M, Woodward M, Levey AS, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. Kidney Int. 2011;79(12):1331–40.

    Article  CAS  PubMed  Google Scholar 

  8. Gansevoort RT, Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, et al. Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population cohorts. Kidney Int. 2011;80(1):93–104.

    Article  CAS  PubMed  Google Scholar 

  9. Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008;372(9638):547–53.

    Article  CAS  PubMed  Google Scholar 

  10. Zannad F, McMurray JJV, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364(1):11–21.

    Article  CAS  PubMed  Google Scholar 

  11. Nagase M. Activation of the aldosterone/mineralocorticoid receptor system in chronic kidney disease and metabolic syndrome. Clin Exp Nephrol. 2010;14(4):303–14.

    Article  CAS  PubMed  Google Scholar 

  12. Shibata S, Mu S, Kawarazaki H, Muraoka K, Ishizawa K, Yoshida S, et al. Rac1 GTPase in rodent kidneys is essential for salt-sensitive hypertension via a mineralocorticoid receptor-dependent pathway. J Clin Invest. 2011;121(8):3233–43.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  13. Gomez-Sanchez CE, Warden M, Gomez-Sanchez MT, Hou X, Gomez-Sanchez EP. Diverse immunostaining patterns of mineralocorticoid receptor monoclonal antibodies. Steroids. 2011;76(14):1541–5.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  14. Rickard AJ, Morgan J, Tesch G, Funder JW, Fuller PJ, Young MJ. Deletion of mineralocorticoid receptors from macrophages protects against deoxycorticosterone/salt-induced cardiac fibrosis and increased blood pressure. Hypertension. 2009;54(3):537–43.

    Article  CAS  PubMed  Google Scholar 

  15. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl J Med. 1999;341(10):709–17.

    Article  CAS  PubMed  Google Scholar 

  16. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348(14):1309–21.

    Article  CAS  PubMed  Google Scholar 

  17. Guo C, Martinez-Vasquez D, Mendez GP, Toniolo MF, Yao TM, Oestreicher EM, et al. Mineralocorticoid receptor antagonist reduces renal injury in rodent models of types 1 and 2 diabetes mellitus. Endocrinology. 2006;147(11):5363–73.

    Article  CAS  PubMed  Google Scholar 

  18. Han SY, Kim CH, Kim HS, Jee YH, Song HK, Lee MH, et al. Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. J Am Soc Nephrol. 2006;17(5):1362–72.

    Article  CAS  PubMed  Google Scholar 

  19. Rocha R, Chander PN, Khanna K, Zuckerman A, Stier CT. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension. 1998;31(1 Pt 2):451–8.

    Article  CAS  PubMed  Google Scholar 

  20. Blasi ER, Rocha R, Rudolph AE, Blomme EAG, Polly ML, Mcmahon EG. Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int. 2003;63(5):1791–800.

    Article  CAS  PubMed  Google Scholar 

  21. Ikeda H, Tsuruya K, Toyonaga J, Masutani K, Hayashida H, Hirakata H, et al. Spironolactone suppresses inflammation and prevents L-NAME–induced renal injury in rats. Kidney Int. 2008;75(2):147–55.

    Article  PubMed  Google Scholar 

  22. Nagase M, Yoshida S, Shibata S, Nagase T, Gotoda T, Ando K, et al. Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribution of fat-derived factors. J Am Soc Nephrol. 2006;17(12):3438–46.

    Article  CAS  PubMed  Google Scholar 

  23. Zitt E, Eller K, Huber JM, Kirsch AH, Tagwerker A, Mayer G, et al. The selective mineralocorticoid receptor antagonist eplerenone is protective in mild anti-GBM glomerulonephritis. Int J Clin Exp Pathol. 2011;4(6):606–15.

    CAS  PubMed Central  PubMed  Google Scholar 

  24. Asai M, Monkawa T, Marumo T, Fukuda S, Tsuji M, Yoshino J, et al. Spironolactone in combination with cilazapril ameliorates proteinuria and renal interstitial fibrosis in rats with anti-Thy-1 irreversible nephritis. Hypertens Res. 2004;27(12):971–8.

    Article  CAS  PubMed  Google Scholar 

  25. Monrad SU, Killen PD, Anderson MR, Bradke A, Kaplan MJ. The role of aldosterone blockade in murine lupus nephritis. Arthritis Res Ther. 2008;10(1):R5.

    Article  PubMed Central  PubMed  Google Scholar 

  26. Fukuda A, Fujimoto S, Iwatsubo S, Kawachi H, Kitamura K. Effects of mineralocorticoid and angiotensin II receptor blockers on proteinuria and glomerular podocyte protein expression in a model of minimal change nephrotic syndrome. Nephrology. 2010;15(3):321–6.

    Article  CAS  PubMed  Google Scholar 

  27. Nakhoul F, Khankin E, Yaccob A, Kawachi H, Karram T, Awaad H, et al. Eplerenone potentiates the antiproteinuric effects of enalapril in experimental nephrotic syndrome. Am J Physiol Renal Physiol. 2008;294(3):F628–37.

    Article  CAS  PubMed  Google Scholar 

  28. Terada Y, Kuwana H, Kobayashi T, Okado T, Suzuki N, Yoshimoto T, et al. Aldosterone-stimulated SGK1 activity mediates profibrotic signaling in the mesangium. J Am Soc Nephrol. 2008;19(2):298–309.

    Article  CAS  PubMed  Google Scholar 

  29. Leroy V, De Seigneux S, Agassiz V, Hasler U, Rafestin-Oblin ME, Vinciguerra M, et al. Aldosterone activates NF-κB in the collecting duct. J Am Soc Nephrol. 2009;20(1):131–44.

    Article  CAS  PubMed  Google Scholar 

  30. D’Agati VD, Kaskel FJ, Falk RJ. Focal segmental glomerulosclerosis. N Engl J Med. 2011;365(25):2398–411.

    Article  PubMed  Google Scholar 

  31. Greka A, Mundel P. Cell biology and pathology of podocytes. Annu Rev Physiol. 2012;74:299–323.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  32. Chen C, Liang W, Jia J, van Goor H, Singhal PC, Ding G. Aldosterone induces apoptosis in rat podocytes: role of PI3-K/Akt and p38MAPK signaling pathways. Nephron Exp Nephrol. 2009;113(1):e26–34.

    Article  CAS  PubMed  Google Scholar 

  33. Zhu C, Huang S, Yuan Y, Ding G, Chen R, Liu B, et al. Mitochondrial dysfunction mediates aldosterone-induced podocyte damage. Am J Pathol. 2011;178(5):2020–31.

    Article  CAS  PubMed  Google Scholar 

  34. Yuan Y, Huang S, Wang W, Wang Y, Zhang P, Zhu C, et al. Activation of peroxisome proliferator-activated receptor-γ coactivator 1α ameliorates mitochondrial dysfunction and protects podocytes from aldosterone-induced injury. Kidney Int. 2012;30:1–19.

    CAS  Google Scholar 

  35. Ogawa Y, Mukoyama M, Yokoi H, Kasahara M, Mori K, Kato Y, et al. Natriuretic peptide receptor guanylyl cyclase-A protects podocytes from aldosterone-induced glomerular injury. J Am Soc Nephrol. 2012;23(7):1198–209.

    Article  CAS  PubMed  Google Scholar 

  36. Fakitsas P, Adam G, Daidié D, van Bemmelen MX, Fouladkou F, Patrignani A, et al. Early aldosterone-induced gene product regulates the epithelial sodium channel by deubiquitylation. J Am Soc Nephrol. 2007;18(4):1084–92.

    Article  CAS  PubMed  Google Scholar 

  37. Toyonaga J, Tsuruya K, Ikeda H, Noguchi H, Yotsueda H, Fujisaki K, et al. Spironolactone inhibits hyperglycemia-induced podocyte injury by attenuating ROS production. Nephrol Dial Transplant. 2011;26(8):2475–84.

    Article  CAS  PubMed  Google Scholar 

  38. Shibata S, Nagase M, Yoshida S, Kawarazaki W, Kurihara H, Tanaka H, et al. Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease. Nat Med. 2008;14(12):1370–6.

    Article  CAS  PubMed  Google Scholar 

  39. Shibata S, Nagase M, Yoshida S, Kawachi H, Fujita T. Podocyte as the target for aldosterone: roles of oxidative stress and SGK1. Hypertension. 2006;49(2):355–64.

    Article  Google Scholar 

  40. Kawarazaki W, Nagase M, Yoshida S, Takeuchi M, Ishizawa K, Ayuzawa N, et al. Angiotensin II- and salt-induced kidney injury through Rac1-mediated mineralocorticoid receptor activation. J Am Soc Nephrol. 2012;23(6):997–1007.

    Article  CAS  PubMed  Google Scholar 

  41. Kitada K, Nakano D, Liu Y, Fujisawa Y, Hitomi H, Shibayama Y, et al. Oxidative stress-induced glomerular mineralocorticoid receptor activation limits the benefit of salt reduction in Dahl salt-sensitive rats. PLoS One. 2012;7(7):e41896.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  42. Nagase M, Ayuzawa N, Kawarazaki W, Ishizawa K, Ueda K, Yoshida S, et al. Oxidative stress causes mineralocorticoid receptor activation in rat cardiomyocytes: role of small GTPase Rac1. Hypertension. 2012;59(2):500–6.

    Article  CAS  PubMed  Google Scholar 

  43. Kobori H, Nangaku M, Navar LG, Nishiyama A. The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev. 2007;59(3):251–87.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  44. Fiebeler A, Nussberger J, Shagdarsuren E, Rong S, Hilfenhaus G, Al-Saadi N, et al. Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage. Circulation. 2005;111(23):3087–94.

    Article  CAS  PubMed  Google Scholar 

  45. Lea WB, Kwak ES, Luther JM, Fowler SM, Wang Z, Ma J, et al. Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high salt. Kidney Int. 2009;75(9):936–44.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  46. Navaneethan SD, Nigwekar SU, Sehgal AR, Strippoli GF. Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2009;4(3):542–51.

    Article  CAS  PubMed  Google Scholar 

  47. Epstein M, Williams GH, Weinberger M, Lewin A, Krause S, Mukherjee R, Patni R, Beckerman B. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol. 2006;1:940–51.

    Article  CAS  PubMed  Google Scholar 

  48. van den Meiracker AH, Baggen RG, Pauli S, Lindemans A, Vulto AG, Poldermans D, et al. Spironolactone in type 2 diabetic nephropathy: effects on proteinuria, blood pressure and renal function. J Hypertens. 2006;24(11):2285–92.

    Article  PubMed  Google Scholar 

  49. Bianchi S, Bigazzi R, Campese VM. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int. 2006;70(12):2116–23.

    CAS  PubMed  Google Scholar 

  50. Chrysostomou A, Pedagogos E, MacGregor L, Becker GJ. Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker. Clin J Am Soc Nephrol. 2006;1(2):256–62.

    Article  CAS  PubMed  Google Scholar 

  51. Mehdi UF, Adams-Huet B, Raskin P, Vega GL, Toto RD. Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J Am Soc Nephrol. 2009;20(12):2641–50.

    Article  CAS  PubMed  Google Scholar 

  52. Nagai Y, Miyata K, Sun GP, Rahman M, Kimura S, Miyatake A, et al. Aldosterone stimulates collagen gene expression and synthesis via activation of ERK1/2 in rat renal fibroblasts. Hypertension. 2005;46(4):1039–45.

    Article  CAS  PubMed  Google Scholar 

  53. Nishiyama A, Yao L, Fan Y, Kyaw M, Kataoka N, Hashimoto K, et al. Involvement of aldosterone and mineralocorticoid receptors in rat mesangial cell proliferation and deformability. Hypertension. 2005;45(4):710–6.

    Article  CAS  PubMed  Google Scholar 

  54. Jeong Y, Chaupin DF, Matsushita K, Yamakuchi M, Cameron SJ, Morrell CN, et al. Aldosterone activates endothelial exocytosis. Proc Natl Acad Sci USA. 2009;106(10):3782–7.

    Article  CAS  PubMed  Google Scholar 

  55. McCurley A, Pires PW, Bender SB, Aronovitz M, Zhao MJ, Metzger D, et al. Direct regulation of blood pressure by smooth muscle cell mineralocorticoid receptors. Nat Med. 2012;18(9):1429–33.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  56. Barish GD, Downes M, Alaynick WA, Yu RT, Ocampo CB, Bookout AL, et al. A nuclear receptor atlas: macrophage activation. Mol Endocrinol. 2005;19(10):2466–77.

    Article  CAS  PubMed  Google Scholar 

  57. Bienvenu LA, Morgan J, Rickard AJ, Tesch GH, Cranston GA, Fletcher EK, et al. Macrophage mineralocorticoid receptor signaling plays a key role in aldosterone-independent cardiac fibrosis. Endocrinology. 2012;153(7):3416–25.

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Division of Chronic Kidney Disease, Department of Nephrology and Endocrinology, The University of Tokyo Graduate School of Medicine, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan

    Kohei Ueda & Miki Nagase

Authors
  1. Kohei Ueda
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Miki Nagase
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Miki Nagase.

About this article

Cite this article

Ueda, K., Nagase, M. Mineralocorticoid receptor activation as an etiological factor in kidney diseases. Clin Exp Nephrol 18, 16–23 (2014). https://doi.org/10.1007/s10157-013-0827-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10157-013-0827-3

Keywords

Search

Navigation